What does JLS Pharma do?

JLS Pharma is a pharmacy in La Bruyère. Private Limited, started on 23 July 2021, 1 establishment.

What is the address of JLS Pharma?

The registered office of JLS Pharma is located at Rue des Closières, Meux 21, 5081 La Bruyère.

Is JLS Pharma still active?

Yes. According to the CBE (31 October 2026) JLS Pharma is active, legal situation “Normale toestand”, started on 23 July 2021.

Is JLS Pharma registered on Peppol?

Yes, JLS Pharma is registered on the Peppol network with ID 0208:0771655091.

What is the enterprise number of JLS Pharma?

The enterprise number of JLS Pharma is BE0771655091.

When was JLS Pharma founded?

JLS Pharma was founded on 23 July 2021.

Who are the directors of JLS Pharma?

According to the 2025 annual accounts, the directors of JLS Pharma are: Christophe SCHEIFF, NOEL JEHOTTE.

Is JLS Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 July 2021; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did JLS Pharma make in 2025?

JLS Pharma posted a profit after taxes of € 71,664 in financial year 2025.

What is the revenue of JLS Pharma?

As a small company, JLS Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 295,086.

How much does an employee at JLS Pharma earn?

The average wage cost per full-time employee at JLS Pharma was € 76,200 in 2025: staff costs of € 198,138 for 2.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does JLS Pharma have?

According to the 2025 annual accounts, JLS Pharma has 2.6 full-time equivalents (FTE).

JLS Pharma (Private Limited) - La Bruyère - BE0771655091

Dossier JLS Pharma, printed on 31 October 2026 from databakkes.be/en/0771655091/jls-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

JLS Pharma from La Bruyère, company number BE0771655091, closed financial year 2025 with a result of € 71,664 after tax. For that financial year JLS Pharma recorded a gross margin of € 295,086 and equity of € 29,426. Compared with financial year 2024, the result moved from € 7,075 to € 71,664. Profitable, and profit is growing. The buffer shrank hard: equity is 70 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.

What it is worth Shrank hard

€ 29,426

▼ 70% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 71,664

▲ € 64,589 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 50,531

▼ 40% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 140,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.6

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 198,138

▲ 5% vs 2024

€ 76,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 60,771

▼ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 42,882

▲ 58% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	€ 1,024,103 Revenue 2023: € 1,024,103 First fiscal year in the series	-	-
Gross margin	€ 307,552 Gross margin 2022: € 307,552 First fiscal year in the series	€ 207,284 Gross margin 2023: € 207,284 ▼ 33% vs 2022 (€ 307,552) Unfavourable step	€ 200,413 Gross margin 2024: € 200,413 ▼ 3% vs 2023 (€ 207,284) Unfavourable step	€ 295,086 Gross margin 2025: € 295,086 ▲ 47% vs 2024 (€ 200,413) Favourable step	▲ 47%
Profit after taxes	€ 50,834 Profit after taxes 2022: € 50,834 First fiscal year in the series	€ 14,854 Profit after taxes 2023: € 14,854 ▼ 71% vs 2022 (€ 50,834) Unfavourable step	€ 7,075 Profit after taxes 2024: € 7,075 ▼ 52% vs 2023 (€ 14,854) Unfavourable step	€ 71,664 Profit after taxes 2025: € 71,664 ▲ € 64,589 vs 2024 (€ 7,075) Favourable step	▲ € 64,589
Equity	€ 75,834 Equity 2022: € 75,834 First fiscal year in the series	€ 90,688 Equity 2023: € 90,688 ▲ 20% vs 2022 (€ 75,834) Favourable step	€ 97,762 Equity 2024: € 97,762 ▲ 8% vs 2023 (€ 90,688) Favourable step	€ 29,426 Equity 2025: € 29,426 ▼ 70% vs 2024 (€ 97,762) Unfavourable step	▼ 70%
Total debts	€ 158,679 Total debts 2022: € 158,679 First fiscal year in the series	€ 136,744 Total debts 2023: € 136,744 ▼ 14% vs 2022 (€ 158,679) Favourable step	€ 120,290 Total debts 2024: € 120,290 ▼ 12% vs 2023 (€ 136,744) Favourable step	€ 203,100 Total debts 2025: € 203,100 ▲ 69% vs 2024 (€ 120,290) Unfavourable step	▲ 69%
Cash	€ 101,812 Cash 2022: € 101,812 First fiscal year in the series	€ 100,467 Cash 2023: € 100,467 ▼ 1% vs 2022 (€ 101,812) Unfavourable step	€ 83,876 Cash 2024: € 83,876 ▼ 17% vs 2023 (€ 100,467) Unfavourable step	€ 50,531 Cash 2025: € 50,531 ▼ 40% vs 2024 (€ 83,876) Unfavourable step	▼ 40%
Retained profit	€ 50,834 Retained profit 2022: € 50,834 First fiscal year in the series	€ 65,688 Retained profit 2023: € 65,688 ▲ 29% vs 2022 (€ 50,834) Favourable step	€ 72,762 Retained profit 2024: € 72,762 ▲ 11% vs 2023 (€ 65,688) Favourable step	€ 4,426 Retained profit 2025: € 4,426 ▼ 94% vs 2024 (€ 72,762) Unfavourable step	▼ 94%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 140,000 Dividend 2025: € 140,000 Unchanged (€ 0) Unchanged
Bank debt	€ 24,998 Bank debt 2022: € 24,998 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 24,998) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 234,512 Balance sheet total 2022: € 234,512 First fiscal year in the series	€ 227,432 Balance sheet total 2023: € 227,432 ▼ 3% vs 2022 (€ 234,512) Unchanged	€ 218,052 Balance sheet total 2024: € 218,052 ▼ 4% vs 2023 (€ 227,432) Unchanged	€ 232,526 Balance sheet total 2025: € 232,526 ▲ 7% vs 2024 (€ 218,052) Unchanged	▲ 7%
Employees (FTE)	2.8 Employees (FTE) 2022: 2.8 First fiscal year in the series	2.6 Employees (FTE) 2023: 2.6 ▼ 0.2 vs 2022 (2.8) Unchanged	2.8 Employees (FTE) 2024: 2.8 ▲ 0.2 vs 2023 (2.6) Unchanged	2.6 Employees (FTE) 2025: 2.6 ▼ 0.2 vs 2024 (2.8) Unchanged	▼ 0.2

Key figures of JLS Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to JLS Pharma?

What happened at JLS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 9, 2026 New annual accounts for financial year 2025: profit of € 71,664 (▲ € 64,589 vs 2024). Source: NBB ↗
2025 Christophe SCHEIFF became a director. NBB
Jul 25, 2021 New establishment in Bütgenbach. KBO
Jul 23, 2021 Start of the company according to the CBE. KBO
2021 NOEL JEHOTTE became a director. NBB

In short

From € 50,834 profit in 2022 to € 71,664 profit in 2025.

Paid € 42,212 in corporate taxes since 2022.

Best year ever: 2025, with € 71,664 profit.

On average € 113,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Christophe SCHEIFF NOEL JEHOTTE

JLS Pharma

Behind JLS Pharma are Christophe SCHEIFF and NOEL JEHOTTE.

Directors

According to the 2025 annual accounts

Christophe SCHEIFF

Director

since 2025

NOEL JEHOTTE

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Closières, Meux 21

5081 La Bruyère

2.319.723.821

Büllinger Strasse 8

4750 Bütgenbach

Active since 25 July 2021

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0771.655.091

VAT number

BE 0771.655.091

Registered office

Rue des Closières, Meux 21, 5081 La Bruyère

Names & denominations

JLS Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 July 2021

Peppol

Active · Active since 14 May 2025

Activities · NACE

Detailhandel in farmaceutische producten

Overige detailhandel in voedingsmiddelen, neg

Vervaardiging van overige farmaceutische producten

Vervaardiging van geneesmiddelen

Detailhandel in cosmetica en toiletartikelen

Vervaardiging van farmaceutische grondstoffen

Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

JLS Pharma

Financials

What happened to JLS Pharma?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions